tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Edema D004487 152 associated lipids
Precancerous Conditions D011230 48 associated lipids
Postoperative Complications D011183 5 associated lipids
Arthritis D001168 41 associated lipids
Arthritis, Experimental D001169 24 associated lipids
Surgical Wound Infection D013530 7 associated lipids
Neoplasm Recurrence, Local D009364 5 associated lipids
Osteonecrosis D010020 5 associated lipids
Hypotension D007022 41 associated lipids
Acute Kidney Injury D058186 34 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Cacciarelli TV et al. An analysis of pretransplantation variables associated with long-term allograft outcome in pediatric liver transplant recipients receiving primary tacrolimus (FK506) therapy. 1999 Transplantation pmid:10507484
Morrissey PE Prope tolerance: is it the end or the means? 2009 Transplantation pmid:19502973
Alloway RR Mounting Clinical Evidence With Tacrolimus Generic Products. 2017 Transplantation pmid:28749820
Prókai Á et al. Calcineurin-inhibition Results in Upregulation of Local Renin and Subsequent Vascular Endothelial Growth Factor Production in Renal Collecting Ducts. 2016 Transplantation pmid:26502369
Todo S et al. Abdominal multivisceral transplantation. 1995 Transplantation pmid:7530873
Lykavieris P et al. Angioedema in pediatric liver transplant recipients under tacrolimus immunosuppression. 2003 Transplantation pmid:12544888
Moffatt SD et al. Potential for improved therapeutic index of FK506 in liposomal formulation demonstrated in a mouse cardiac allograft model. 1999 Transplantation pmid:10342309
Bierer BE et al. Mechanisms of immunosuppression by FK506. Preservation of T cell transmembrane signal transduction. 1990 Transplantation pmid:1694317
Woodle ES et al. FK506--reversal of humorally mediated cardiac allograft rejection in the presence of preformed anti-class I antibody. 1993 Transplantation pmid:7504346
Yin DP et al. Lewis rat pancreas, but not cardiac xenografts, are resistant to anti-gal antibody mediated hyperacute rejection. 2001 Transplantation pmid:11391223
Eberhard OK et al. How best to use tacrolimus (FK506) for treatment of steroid- and OKT3-resistant rejection after renal transplantation. 1996 Transplantation pmid:8629294
Bruce DS et al. Multicenter survey of daclizumab induction in simultaneous kidney-pancreas transplant recipients. 2001 Transplantation pmid:11726823
Loucaidou M et al. Five-year results of kidney transplantation under tacrolimus-based regimes: the persisting significance of vascular rejection. 2003 Transplantation pmid:14557763
Toso C et al. Insulin independence after conversion to tacrolimus and sirolimus-based immunosuppression in islet-kidney recipients. 2003 Transplantation pmid:14557767
Muthukumar T et al. HIV-infected kidney graft recipients managed with an early corticosteroid withdrawal protocol: clinical outcomes and messenger RNA profiles. 2013 Transplantation pmid:23503504
King-Biggs MB et al. Airway anastomotic dehiscence associated with use of sirolimus immediately after lung transplantation. 2003 Transplantation pmid:12792493
Vu MD et al. Combination therapy of malononitrilamide FK778 with tacrolimus on cell proliferation assays and in rats receiving renal allografts. 2003 Transplantation pmid:12792496
Hricik DE et al. Long-term graft outcomes after steroid withdrawal in African American kidney transplant recipients receiving sirolimus and tacrolimus. 2007 Transplantation pmid:17297401
Roberts JP et al. Reversal of chronic rejection after treatment failure with FK506 and RS61443. 1993 Transplantation pmid:7692634
Cacciarelli TV et al. Oral tacrolimus (FK506) induction therapy in pediatric orthotopic liver transplantation. 1996 Transplantation pmid:8610416
Jain A et al. Comparative long-term evaluation of tacrolimus and cyclosporine in pediatric liver transplantation. 2000 Transplantation pmid:10972220
Sharif A et al. Insulin resistance indexes in renal transplant recipients maintained on tacrolimus immunosuppression. 2010 Transplantation pmid:20145524
Abu-Qaoud MS et al. Lack of relationship between microvascular and macrovascular disease in heart transplant recipients. 2012 Transplantation pmid:23044666
Kaplan B et al. Frequency of hyperkalemia in recipients of simultaneous pancreas and kidney transplants with bladder drainage. 1996 Transplantation pmid:8900321
Woodward RS et al. Renal graft survival and calcineurin inhibitor. 2005 Transplantation pmid:16177637
Merkle M et al. The effect of sevelamer on tacrolimus target levels. 2005 Transplantation pmid:16177649
Gruber SA et al. Initial results of solitary pancreas transplants performed without regard to donor/recipient HLA mismatching. 2000 Transplantation pmid:10933170
Shapiro R et al. Alopecia as a consequence of tacrolimus therapy. 1998 Transplantation pmid:9603186
Muraki T et al. Effects of cyclosporine and FK506 on in vitro high shear-induced platelet reactivity in rat and human non-anticoagulated blood. 1998 Transplantation pmid:9583878
Fernandez LA et al. The effects of maintenance doses of FK506 versus cyclosporin A on glucose and lipid metabolism after orthotopic liver transplantation. 1999 Transplantation pmid:10589951
Kadry Z et al. Kaposi's sarcoma in liver transplant recipients on FK506. 1998 Transplantation pmid:9583882
Batten P et al. Human T cell responses to human and porcine endothelial cells are highly sensitive to cyclosporin A and FK506 in vitro. 1999 Transplantation pmid:10589954
Uemura T et al. Single dose of alemtuzumab induction with steroid-free maintenance immunosuppression in pancreas transplantation. 2011 Transplantation pmid:21841541
Thorp M et al. The effect of conversion from cyclosporine to tacrolimus on gingival hyperplasia, hirsutism and cholesterol. 2000 Transplantation pmid:10762229
Sulanc E et al. New-onset diabetes after kidney transplantation: an application of 2003 International Guidelines. 2005 Transplantation pmid:16249743
Jacobson PA et al. Novel polymorphisms associated with tacrolimus trough concentrations: results from a multicenter kidney transplant consortium. 2011 Transplantation pmid:21206424
Fealy MJ et al. Association of down-regulation of cytokine activity with rat hind limb allograft survival. 1995 Transplantation pmid:7539555
Yang H et al. Liposomal encapsulation significantly enchances the immunosuppressive effect of tacrolimus in a discordant islet xenotransplant model. 2002 Transplantation pmid:11907415
St A Nunes FA and Lucey MR Searching for a balance when applying immunosuppression after liver transplantation. 2001 Transplantation pmid:11258425
Opelz G and Döhler B Influence of immunosuppressive regimens on graft survival and secondary outcomes after kidney transplantation. 2009 Transplantation pmid:19300179
Rostambeigi N et al. Unique cellular and mitochondrial defects mediate FK506-induced islet β-cell dysfunction. 2011 Transplantation pmid:21200364
Mikhalski D et al. Cold ischemia is a major determinant of acute rejection and renal graft survival in the modern era of immunosuppression. 2008 Transplantation pmid:18401260
Nankivell BJ et al. Oral cyclosporine but not tacrolimus reduces renal transplant blood flow. 2004 Transplantation pmid:15167607
Gibson SW et al. Nutritional immunomodulation leads to enhanced allograft survival in combination with cyclosporine A and rapamycin, but not FK506. 2000 Transplantation pmid:10852592
Ciancio G et al. A randomized pilot study of donor stem cell infusion in living-related kidney transplant recipients receiving alemtuzumab. 2013 Transplantation pmid:23903014
Warty V et al. FK506: a novel immunosuppressive agent. Characteristics of binding and uptake by human lymphocytes. 1988 Transplantation pmid:2458643
Lerut J et al. Anti-CD2 monoclonal antibody and tacrolimus in adult liver transplantation. 2005 Transplantation pmid:16314784
Komori K et al. The role of graft and host accommodation in a hamster-to-rat cardiac transplantation model. 2008 Transplantation pmid:18192920
Meiser BM et al. Tacrolimus or cyclosporine: which is the better partner for mycophenolate mofetil in heart transplant recipients? 2004 Transplantation pmid:15446320
Uemoto S et al. Experience with FK506 in living-related liver transplantation. 1993 Transplantation pmid:7679528